U266

U266/U266细胞系/U266细胞株/U266人骨髓瘤细胞

Cell line name U266B1

Synonyms U266-B1; U266 B1; U-266; U 266; U266; U266S; U266BL; U266 Bl; 266 Bl

Accession CVCL_0566

Resource Identification Initiative To cite this cell line use: U266B1 (RRID:CVCL_0566)

Comments Group: Hybridoma fusion partner cell line.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Population: Caucasian.

Characteristics: Produces IgE lambda.

Doubling time: 108-144 hours (PubMed=4104421); ~55 hours (DSMZ=ACC-9).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: B-cell; CL=CL_0000236.

PubMed=9685479; DOI=10.1093/nar/26.16.3651; PMCID=PMC147775

Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.

Telomere analysis by fluorescence in situ hybridization and flow cytometry.

Nucleic Acids Res. 26:3651-3656(1998)

 

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5

Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H.C., Bast B.J.E.G.

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.

Cancer Genet. Cytogenet. 109:99-107(1999)

 

PubMed=10557056; DOI=10.1038/sj.leu.2401563

Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.

Detection of MUM1/IRF4-IgH fusion in multiple myeloma.

Leukemia 13:1812-1816(1999)

 

PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x

Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille R., Amiot M.

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Br. J. Haematol. 107:392-395(1999)

 

DOI=10.1007/0-306-46877-8_4

Jernberg-Wiklund H., Nilsson K.

Multiple myeloma cell lines.

(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

 

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2

Drexler H.G., Matsuo Y.

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Leuk. Res. 24:681-703(2000)

 

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

 

PubMed=11154231; DOI=10.1182/blood.V97.2.516

Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., Sundan A.

Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

Blood 97:516-522(2001)